ECM
ARGS

Element Capital Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Element Capital Management’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,140
Closed -$30K – 148
2017
Q2 		$30K Buy
+4,140
New +$35.3K 0.01% 134

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Element Capital Management's ARGS Position: Q3 2017 in Review

Element Capital Management sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2017, closing a stake of 4,140 shares — an estimated $30K sold.

Element Capital Management first reported a position in ARGS in Q2 2017 and held it in 1 quarter. The position peaked at $30K in Q2 2017. 29 funds tracked by Wall St. Rank hold ARGS as of Q3 2017.

  • Element Capital Management reported no remaining Argos Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Element Capital Management sold 4,140 Argos Therapeutics, Inc. shares in Q3 2017, an estimated $30K.
  • Element Capital Management first reported a position in Argos Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Element Capital Management's Argos Therapeutics, Inc. position peaked at $30K in Q2 2017.
  • 29 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2017.

Based on Element Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.